We are live on
!
Find out more
T
TOBAM Portfolio holdings
AUM
$412M
1-Year Est. Return
18.33%
This Fund
S&P 500
This Quarter
Est. Return
-7.74%
1 Year Est. Return
+18.33%
3 Year Est. Return
+56.05%
5 Year Est. Return
+49%
10 Year Est. Return
+255.15%
AUM
$1.6B
AUM Growth
-$392M
(-20%)
Cap. Flow
-$203M
Cap. Flow
% of AUM
-12.69%
Top 10 Holdings %
Top 10 Hldgs %
25.61%
Holding
503
New
74
Increased
178
Reduced
101
Closed
74
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Quest Diagnostics
DGX
|
+$24.5M |
| 2 |
Church & Dwight Co
CHD
|
+$19.6M |
| 3 |
Eversource Energy
ES
|
+$18.2M |
| 4 |
Expedia Group
EXPE
|
+$17.6M |
| 5 |
Kimberly-Clark
KMB
|
+$17.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$31.2M |
| 2 |
Conagra Brands
CAG
|
+$27M |
| 3 |
SEE
Sealed Air
SEE
|
+$22.8M |
| 4 |
Eli Lilly
LLY
|
+$22.1M |
| 5 |
Regency Centers
REG
|
+$20.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 28% |
| 2 | Consumer Staples | 25.89% |
| 3 | Communication Services | 10.3% |
| 4 | Technology | 7.09% |
| 5 | Materials | 6.85% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Pfizer
PFE
$164B
| $46.4M | 2.91% |
885,098
-149,451
| -14% | -$7.62M |
|
2
General Mills
GIS
$21B
| $44.9M | 2.81% |
594,592
-243,263
| -29% | -$17M |
|
|
3
Kimberly-Clark
KMB
$35.9B
| $43.7M | 2.74% |
323,296
+132,681
| +70% | +$17.5M |
|
4
Merck
MRK
$376B
| $43.6M | 2.73% |
477,807
+119,071
| +33% | +$10.6M |
|
|
K
5
DELISTED
Kellanova
K
| $40.7M | 2.55% |
607,318
-167,756
| -22% | -$10.9M |
|
6
Clorox
CLX
$11.4B
| $40.7M | 2.55% |
288,398
-50,947
| -15% | -$7.28M |
|
7
Becton Dickinson
BDX
$51.1B
| $37.8M | 2.37% |
153,221
-11,385
| -7% | -$2.89M |
|
8
Hormel Foods
HRL
$11.9B
| $37.7M | 2.36% |
796,098
-84,912
| -10% | -$4.24M |
|
9
J.M. Smucker
SJM
$13.7B
| $37.1M | 2.32% |
289,743
-41,656
| -13% | -$5.56M |
|
|
EA
10
DELISTED
Electronic Arts
EA
| $36.3M | 2.27% |
298,330
+96,482
| +48% | +$12.3M |
|
11
Gen Digital
GEN
$18.8B
| $36.2M | 2.27% |
1,650,117
+46,097
| +3% | +$1.13M |
|
|
12
Church & Dwight Co
CHD
$23.4B
| $35.9M | 2.25% |
387,276
+207,082
| +115% | +$19.6M |
|
|
13
Eli Lilly
LLY
$1.03T
| $35.9M | 2.25% |
110,650
-73,636
| -40% | -$22.1M |
|
14
C.H. Robinson
CHRW
$17.1B
| $35.9M | 2.25% |
353,763
+75,367
| +27% | +$7.87M |
|
|
15
Quest Diagnostics
DGX
$26.4B
| $34.5M | 2.16% |
259,352
+179,847
| +226% | +$24.5M |
|
16
Biogen
BIIB
$33.2B
| $33M | 2.07% |
161,853
-15,840
| -9% | -$3.24M |
|
17
Campbell Soup
CPB
$6.6B
| $33M | 2.07% |
686,574
-198,320
| -22% | -$9.34M |
|
18
Newmont
NEM
$137B
| $30.7M | 1.93% |
515,246
+70,468
| +16% | +$4.99M |
|
19
Neurocrine Biosciences
NBIX
$16.1B
| $29.9M | 1.87% |
306,494
+90,037
| +42% | +$8.31M |
|
20
Consolidated Edison
ED
$40.2B
| $28.2M | 1.77% |
296,158
-51,414
| -15% | -$4.9M |
|
21
Dollar Tree
DLTR
$24.6B
| $27.7M | 1.73% |
177,463
-103,667
| -37% | -$16.4M |
|
22
Alnylam Pharmaceuticals
ALNY
$35.4B
| $26.3M | 1.65% |
180,101
+24,516
| +16% | +$3.48M |
|
23
Franco-Nevada
FNV
$52.1B
| $22.2M | 1.39% |
169,313
-47,172
| -22% | -$6.98M |
|
24
Assurant
AIZ
$14.2B
| $21.3M | 1.33% |
123,020
-50,886
| -29% | -$9.22M |
|
25
Moderna
MRNA
$59.4B
| $21M | 1.31% |
146,771
-7,406
| -5% | -$1.06M |
|
Similar funds
EC
WIP
KP
MP
AWP
THCM
PA
HP
TOBAM's Q2 2022 Portfolio in Review
As of Q2 2022, TOBAM held 503 positions worth $1.6B, down 20% from $1.99B the previous quarter. Its ten largest holdings account for 26% of the portfolio.
TOBAM withdrew a net $203M in Q2 2022, closing 74 positions and reducing 101 holdings. Its most notable exit was Novavax, an estimated $12.8M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 28% of assets, up from 26% a quarter earlier, followed by Consumer Staples and Communication Services.
Against the trend, TOBAM opened a new position in Expedia Group worth $11.8M.
- TOBAM's largest Q2 2022 buy was Expedia Group: 124,451 shares worth $11.8M.
- TOBAM added most to Quest Diagnostics in Q2 2022, an estimated $24.5M increase.
- TOBAM's biggest Q2 2022 reduction was Gilead Sciences, cutting an estimated $31.2M.
- TOBAM fully exited Novavax in Q2 2022, selling an estimated $12.8M.
- TOBAM's ten largest holdings make up 26% of its $1.6B portfolio in Q2 2022.
- TOBAM opened 74 new positions and closed 74 in Q2 2022.
- TOBAM's portfolio value fell 20% quarter-over-quarter to $1.6B.
Based on TOBAM's 13F filing for Q2 2022, filed 2 Aug 2022.